ArticleExperimental and molecular pathology2009
Metabolic profiling identifies lung tumor responsiveness to erlotinib.
Article in Experimental and molecular pathology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation.The Journal of clinical investigation · 2015Trial
- Stable isotope-resolved metabolomics analyses of metabolic phenotypes reveal variable glutamine metabolism in different patient-derived models of non-small cell lung cancer from a single patient.Metabolomics : Official journal of the Metabolomic Society · 2024Article
- Metabolomic and proteomic applications to exercise biomedicine.Translational exercise biomedicine · 2024Review
- Evaluation of Lung Cancer Patient Response to First-Line Chemotherapy by Integration of Tumor Core Biopsy Metabolomics with Multiscale Modeling.Annals of biomedical engineering · 2023Article
- Article
- Longitudinal Pharmacometabonomics for Predicting Malignant Tumor Patient Responses to Anlotinib Therapy: Phenotype, Efficacy, and Toxicity.Frontiers in oncology · 2020Article
- Metabolic characteristics revealing cell differentiation of nasopharyngeal carcinoma by combining NMR spectroscopy with Raman spectroscopy.Cancer cell international · 2019Article
- Comparison of clinical and radiological characteristics between anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation in treatment naïve advanced lung adenocarcinoma.Journal of thoracic disease · 2017Article
- Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage I/II lung adenocarcinoma.Thoracic cancer · 2017Article
- Cancer-Specific Production of N-Acetylaspartate via NAT8L Overexpression in Non-Small Cell Lung Cancer and Its Potential as a Circulating Biomarker.Cancer prevention research (Philadelphia, Pa.) · 2016Article
- Review of mass spectrometry-based metabolomics in cancer research.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2013Review
- Liquid chromatography/mass spectrometry methods for measuring dipeptide abundance in non-small-cell lung cancer.Rapid communications in mass spectrometry : RCM · 2013Article
- Challenges and opportunities of metabolomics.Journal of cellular physiology · 2012Review
- Stable isotope-resolved metabolomics and applications for drug development.Pharmacology & therapeutics · 2012Review
- Stable isotope resolved metabolomics of lung cancer in a SCID mouse model.Metabolomics : Official journal of the Metabolomic Society · 2011Article
- Can nuclear magnetic resonance (NMR) spectroscopy reveal different metabolic signatures for lung tumours?Virchows Archiv : an international journal of pathology · 2010Article
- Individualized medicine 2010.Journal of cellular and molecular medicine · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
A subtype of non-small cell lung cancer, bronchioalveolar adenocarcinoma (BAC), is more prevalent in Asian female non-smokers, and is more likely to respond to treatment with tyrosine kinase inhibitors such as erlotinib and gefitinib. Nuclear magnetic resonance and mass spectrometry-based metabolomic analysis of extracts from two different lung lesions and surrounding non-cancerous tissues of a BAC patient showed novel protein and phospholipid-associated metabolic differences that correlated with tumor development as well as PET and erlotinib sensitivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.